The mechanism of Genistein in the genesis and development of malignant tumor

doi:10.3760/cma.j.issn.1673-422X.2016.08.011

Abstract

Abstract: Genistein, as a kind of natural inhibitor of tyrosinespecific protein kinases from soybean extracts, has been proved to be closely related to the development of various malignancy tumors such as breast cancer, ovarian cancer and prostate cancer. Studies in vivo and in vitro have indicated that Genistein can inhibit tumor proliferation, invasion and metastasis, induce apoptosis and has the function of antiangiogenesis by combining with estrogen receptor in order to play anticancer effect, which suggest that Genistein may become a new drug in clinical treatment of tumor in the future.

Key words: Neoplasms, Molecular mechanisms of pharmacological action, Genistein

Xiong Ting, Li Liding, Yan Xin, Xie Feiyan, Liao Caiqin, Lu Kaiqiang, Liu Xiaowang, Tu Jian. The mechanism of Genistein in the genesis and development of malignant tumor[J]. Journal of International Oncology, 2016, 43(8): 609-611.

References

［1］ Grabowski M, Banecki B, Kadziński L, et al. Genistein inhibits activities of methylenetetrahydrofolate reductase and lactate dehydrogenase, enzymes which use NADH as a substrate［J］. Biochem Biophys Res Commun, 2015, 465(3): 363-367. DOI: 10.1016/j.bbrc.2015.08.004. ［2］Kim YS, Choi KC, Hwang KA. Genistein suppressed epithelialmesenchymal transition and migration efficacies of BG1 ovarian cancer cells activated by estrogenic chemicals via estrogen receptor pathway and downregulation of TGF-β signaling pathway［J］. Phytomedicine, 2015, 22(11): 993-999. DOI: 10.1016/j.phymed.2015.08.003. ［3］Zhu J, Zhang C, Qing Y, et al. Genistein induces apoptosis by stabilizing intracellular p53 protein through an APE1mediated pathway［J］. Free Radic Biol Med, 2015, 86: 209-218. DOI: 10.1016/j.freeradbiomed.2015.05.030. ［4］ Yang X, Belosay A, Hartman JA, et al. Dietary soy isoflavones increase metastasis to lungs in an experimental model of breast cancer with bone micro-tumors［J］. Clin Exp Metastasis, 2015, 32(4): 323-333. DOI: 10.1007/s10585-015-9709-2. ［5］Mahmoud AM, AlAlem U, Ali MM, et al. Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation［J］. J Steroid Biochem Mol Biol, 2015, 152: 62-75. DOI: 10.1016/j.jsbmb.2015.04.018. ［6］Liu X, Sun C, Jin X, et al. Genistein enhances the radiosensitivity of breast cancer cells via G2/M cell cycle arrest and apoptosis［J］. Molecules, 2013, 18(11): 13200-13217. DOI: 10.3390/molecules181113200. ［7］Zhang L, Yang B, Zhou K, et al. Potential therapeutic mechanism of genistein in breast cancer involves inhibition of cell cycle regulation［J］. Mol Med Rep, 2015, 11(3): 1820-1826. DOI: 10.3892/mmr.2014.2907. ［8］Ouyang G, Yao L, Ruan K, et al. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways［J］. Cell Biol Int, 2009, 33(12): 1237-1244. DOI: 10.1016/j.cellbi.2009.08.011. ［9］Russo M, Russo GL, Daglia M, et al. Understanding genistein in cancer: the "good" and the "bad" effects: a review［J］. Food Chem, 2016, 196: 589-600. DOI: 10.1016/j.foodchem.2015.09.085. ［10］ Sahin K, Tuzcu M, Basak N, et al. Sensitization of cervical cancer cells to cisplatin by genistein: the role of NF-κB and Akt/mTOR signaling pathways［J］. J Oncol, 2012, 2012: 461562. DOI: 10.1155/2012/461562. ［11］ Qian Y, Cao L, Guan T, et al. Protection by genistein on cortical neurons against oxidative stress injury via inhibition of NF-kappaB, JNK and ERK signaling pathway［J］. Pharm Biol, 2015, 53(8): 1124-1132. DOI: 10.3109/13880209.2014.962057. ［12］ Lee H, Ko JH, Baek SH, et al. Embelin inhibits invasion and migration of MDA-MB-231 breast cancer cells by suppression of CXC chemokine receptor 4, matrix metalloproteinases-9/2, and epithelialmesenchymal transition［J］. Phytother Res, 2016, In press. DOI: 10.1002/ptr.5612. ［13］ Karsli-Ceppioglu S, Ngollo M, Judes G, et al. The role of soy phytoestrogens on genetic and epigenetic mechanisms of prostate cancer［J］. Enzymes, 2015, 37: 193-221. DOI: 10.1016/bs.enz.2015.05.004. ［14］ Cojocneanu Petric R, Braicu C, Raduly L, et al. Phytochemicals modulate carcinogenic signaling pathways in breast and hormonerelated cancers［J］. Onco Targets Ther, 2015, 8: 2053-2066. DOI: 10.2147/OTT.S83597. ［15］ Latocha M, P-onka J, Kumierz D, et al. Transcripional activity of genes encoding MMPs and TIMPs in breast cancer cells treated by genistein and in normal cancerassociated fibroblasts—in vitro studies［J］. Acta Pol Pharm, 2014, 71(6): 1095-1102. ［16］ Vantyghem SA, Wilson SM, Postenka CO, et al. Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model［J］. Cancer Res, 2005, 65(8): 3396-3403. ［17］ Xia J, Cheng L, Mei C, et al. Genistein inhibits cell growth and invasion through regulation of miR-27a in pancreatic cancer cells［J］. Curr Pharm Des, 2014, 20(33): 5348-5353. ［18］ Zhang HY, Cui J, Zhang Y, et al. Isoflavones and prostate cancer: a review of some critical issues［J］. Chin Med J (Engl), 2016, 129(3): 341-347. DOI: 10.4103/0366-6999.174488. ［19］ Chen J, Duan Y, Zhang X, et al. Genistein induces apoptosis by the inactivation of the IGF-1R/p-Akt signaling pathway in MCF-7 human breast cancer cells［J］. Food Funct, 2015, 6(3): 995-1000. DOI: 10.1039/c4fo01141d. ［20］ Choi EJ, Jung JY, Kim GH. Genistein inhibits the proliferation and differentiation of MCF-7 and 3T3-L1 cells via the regulation of ER expression and induction of apoptosis［J］. Exp Ther Med, 2014, 8(2): 454-458. ［21］ Varinska L, Gal P, Mojzisova G, et al. Soy and breast cancer: focus on angiogenesis［J］. Int J Mol Sci, 2015, 16(5): 1172811749. DOI: 10.3390/ijms160511728. ［22］ Fernandez AR, Husain R. Vascular endothelial growth factor, soluble fmslike tyrosine kinase 1 and genisteininduced changes in the vascular reactivity of rat′s aorta［J］. J Obstet Gynaecol Res, 2015, 41(2): 277-282. DOI: 10.1111/jog.12511. ［23］ KarsliCeppioglu S, Ngollo M, Judes G, et al. The role of soy phytoestrogens on genetic and epigenetic mechanisms of prostate cancer［J］. Enzymes, 2015, 37: 193-221. DOI: 10.1016/bs.enz.2015.05.004. ［24］ Rigalli JP, Ciriaci N, Arias A, et al. Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity［J］. PLoS One, 2015, 10(3): e0119502. DOI: 10.1371/journal.pone.0119502.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.